Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial tests the safety, side effects, and best dose of camonsertib in combination with stereotactic body radiation therapy in controlling disease in patients with head and neck squamous cell cancer that has come back after a period of improvement (recurrent) or that cannot be removed by surgery (unresectable). Camonsertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Giving camonsertib in combination with stereotactic body radiation therapy may help control disease in patients with recurrent or unresectable head and neck squamous cell cancers.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie rak płaskobrzegi głowy i szyi (jamy ustnej, gardła, krtani, gardła dolnego, zatok obocznych) lub powiększone węzły szyjne nieznanego pochodzenia - nawracający lub niemożliwy do chirurgicznego usunięcia
- •Nawrót nowotworu w obszarze wcześniej poddanym radioterapii (dawka 30-80 Gy)
- •Ukończona poprzednia radioterapia co najmniej 6 miesięcy przed włączeniem do badania
- •Mierzalne zmiana nowotworowa widoczna w obrazowaniu (CT szyi, CT klatki piersiowej lub PET/CT)
- •Wiek co najmniej 18 lat
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
UPMC Hillman Cancer Center
Pittsburgh, United States
Trial contact
Site Public Contact
Yvonne M. Mowery
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/4/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.